Aimee Talleur

Aimee Talleur leads innovative natural killer cell therapy programs for pediatric leukemia at St. Jude, developing CAR-NK and memory-like NK cell platforms that offer potential advantages over T cell-based approaches in safety and manufacturability. Her research on haplo-identical NK cell infusions has demonstrated promising efficacy in pediatric AML with minimal graft-versus-host disease risk. She is advancing next-generation NK cell engineering strategies for pediatric solid tumors.